U.S. Markets closed

ABBV1210115C00110000

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
57.250.00 (0.00%)
At close: 5:05PM EDT
Full screen
Previous Close57.25
OpenN/A
Bid0.00
Ask0.00
StrikeN/A
Expire Date2021-01-15
Day's Range57.25 - 57.25
Contract RangeN/A
VolumeN/A
Open InterestN/A
  • Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
    PR Newswire

    Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference

    Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA) across multiple therapeutic and cosmetic indications. Data includes long-term immunogenicity rates across 10 therapeutic and aesthetic indications, analyses from the Adult Spasticity International Registry (ASPIRE) study and Cervical Dystonia Patient Registry for BOTOX® Efficacy (CD-PROBE), reviewing adherence to onabotulinumtoxinA treatment in patients with spasticity and efficacy and tolerability in patients with cervical dystonia, respectively. Also to be presented are data on incontinence product use and associated costs in patients with overactive bladder treated with onabotulinumtoxinA. Additionally, results from a randomized controlled clinical trial on the efficacy and safety of three active doses of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children and findings from a study on the safety, pharmacodynamic response and treatment satisfaction, with increasing doses of onabotulinumtoxinA in patients with moderate to severe dynamic glabellar lines will be presented. These data will be presented at the TOXINS 2021 Virtual Conference, organized by The International Neurotoxin Association (INA), January 16-17.

  • TheStreet.com

    Best Healthcare Stocks to Buy for 2021

    Real Money contributor Stephen Guilfoyle checks which sector names could perform best over the coming year.

  • AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
    Zacks

    AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

    AbbVie (ABBV) closed at $111.63 in the latest trading session, marking a -0.73% move from the prior day.